EHA 2015 | Monoclonal antibodies for the treatment of multiple myeloma
Thierry Facon
• 12 Jun 2015
At the 20th Congress of the European Hematology Association (EHA), Thierry Facon, MD, of the University Hospital Hurriez, Lille, France, explains that monoclonal antibodies (mAbs) are likely to play a key role in progress in treating patients with multiple myeloma. mAbs of interest include elotuzumab, a mAb targeting Signaling Lymphocytic Activation Molecule F7 (SLAMF7), and the anti-CD38 mAbs, daratumumab, SAR650984, and MOR202.
